1. 2011
  2. The 'gatekeeper' hypothesis challenged in a human cervico-vaginal tissue model for HIV-1 transmission [letter]. / Ariën, KK; Gali, Y; Vanham, G.

    In: Mucosal Immunology, Vol. 4, No. 1, 2011, p. 121-122.

    Research output: Contribution to journalLetter

  3. Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained. / Balla-Jhagjhoorsingh, SS; Willems, B; Heyndrickx, L; Heyndrickx, L; Vereecken, K; Janssens, W; Seaman, MS; Corti, D; Lanzavecchia, A; Davis, D; Vanham, G.

    In: PLoS ONE, Vol. 6, No. 10, 2011, p. e25488.

    Research output: Contribution to journalA1: Web of Science-article

  4. An interferon-gamma ELISPOT assay with two cytotoxic T cell epitopes derived from HTLV-1 Tax region 161-233 discriminates HTLV-1-associated myelopathy/tropical spastic paraparesis patients from asymptomatic HTLV-1 carriers in a Peruvian population. / Best, I; López, G; Talledo, M; MacNamara, A; Verdonck, K; González, E; Tipismana, M; Asquith, B; Gotuzzo, E; Vanham, G; Clark, D.

    In: AIDS Research and Human Retroviruses, Vol. 27, No. 11, 2011, p. 1207-1212.

    Research output: Contribution to journalA1: Web of Science-article

  5. Longitudinal study of primary HIV-1 isolates in drug-naive individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies. / Haldar, B; Burda, S; Williams, C; Heyndrickx, L; Vanham, G; Gorny, MK; Nyambi, P.

    In: PLoS ONE, Vol. 6, No. 2, 2011, p. e17253.

    Research output: Contribution to journalA1: Web of Science-article

  6. DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. / Hijazi, K; Wang, Y; Scala, C; Jeffs, S; Longstaff, C; Stieh, D; Haggarty, B; Vanham, G; Schols, D; Balzarini, J; Jones, IM; Hoxie, J; Shattock, R; Kelly, CG.

    In: PLoS ONE, Vol. 6, No. 12, 2011, p. e28307.

    Research output: Contribution to journalA1: Web of Science-article

  7. Human Immunodeficiency Virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. / Selhorst, P; Vazquez, AC; Terrazas-Aranda, K; Michiels, J; Vereecken, K; Heyndrickx, L; Weber, J; Quiñones-Mateu, ME; Ariën, KK; Vanham, G.

    In: Antimicrobial Agents and Chemotherapy, Vol. 55, No. 4, 2011, p. 1403-1413.

    Research output: Contribution to journalA1: Web of Science-article

  8. Control of viral replication after cessation of HAART. / Van Gulck, E; Heyndrickx, L; Bracke, L; Coppens, S; Florence, E; Buvé, A; Lewi, P; Vanham, G.

    In: Aids Research and Therapy, Vol. 8, 2011, p. 6.

    Research output: Contribution to journalA4: Article in journal not included in A1, A2 or A3

  9. Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) [letter]. / Venkatraj, M; Ariën, KK; Heeres, J; Dirié, B; Joossens, J; Van Goethem, S; Van der Veken, P; Michiels, J; Vande Velde, CML; Vanham, G; Lewi, PJ; Augustyns, K.

    In: Bioorganic and Medicinal Chemistry, Vol. 19, No. 20, 2011, p. 5924-5934.

    Research output: Contribution to journalA1: Web of Science-article

  10. 2010
  11. First real success for anti-HIV gel: a new start for HIV microbicides? [editorial]. / Ariën, KK; Vanham, G.

    In: Future Microbiology, Vol. 5, No. 11, 2010, p. 1621-1623.

    Research output: Contribution to journalEditorial

  12. Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses. / De Haes, W; De Koker, S; Pollard, C; Atkinson, D; Vlieghe, E; Hoste, J; Rejman, J; De Smedt, S; Grooten, J; Vanham, G; Van Gulck, E.

    In: Molecular Therapy, Vol. 18, No. 7, 2010, p. 1408-1416.

    Research output: Contribution to journalA1: Web of Science-article

Previous 1...3 4 5 6 7 8 9 10 ...20 Next

ID: 4718